New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
20:25 EDTWMT, WMT, PRGO, PRGO, KSS, KSS, AAP, AAP, HMHC, HMHC, RRGB, RRGB, BGG, BGGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Wal-Mart (WMT), consensus $1.21; Perrigo (PRGO), consensus $1.55; Kohl's (KSS), consensus $1.07; Advance Auto Parts (AAP), consensus $2.01; Houghton Mifflin (HMHC), consensus 14c; Red Robin (RRGB), consensus 90c; and Briggs & Stratton (BGG), consensus 36c.
News For WMT;PRGO;KSS;AAP;HMHC;RRGB;BGG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 17, 2015
15:42 EDTWMTWal-Mart to slash layer of in-store management, Bloomberg reports
Subscribe for More Information
15:05 EDTPRGOTeva weighing potential bid for Mylan, WSJ reports
Teva Pharmaceutical (TEVA) is weighing a takeover bid for Mylan (MYL), according to the Wall Street Journal, citing people familiar with the matter. This comes one week after Mylan made a $28.9B acquisition offer for Perrigo (PRGO), the Journal added. Reference Link
14:54 EDTPRGOPerrigo trims losses after Mylan says committed to acquisition proposal
Subscribe for More Information
14:51 EDTPRGOMylan says fully committed to Perrigo bid after speculation on Teva interest
Subscribe for More Information
14:47 EDTPRGOMylan says fully committed to stand-alone strategy, proposal to buy Perrigo
Subscribe for More Information
14:31 EDTPRGOMylan jumps after reports of potential bid from Teva
Shares of Mylan (MYL) jumped in afternoon trading after The Wall Street Journal and Bloomberg separately reported that Teva (TEVA) is exploring a takeover offer for the company. Both reports, which each cited sources, said Teva is evaluating a bid internally, but that the company has not made any formal offer as of yet. WHAT'S NOTABLE: In a note to investors this morning, analysts at Cowen said the approval of a generic version of Teva's 20mg Copaxone should spur management to make a value-creating decision to acquire Mylan. The firm also believes in Teva's skill in protecting its Copaxone asset and said now is the time to pursue aggressive strategic actions. Cowen reiterated its Outperform rating and $100 price target on Teva shares. ANOTHER TO WATCH: On April 8, Mylan announced that it delivered to Perrigo's Chairman on April 6 a non-binding proposal to buy the company for $205 per share in a combination of cash and Mylan stock. RBC Capital analyst Randall Stanicky said earlier this week he believed Perrigo may be engaging other companies in talks after Mylan made its offer public. Stanicky sees no clear competing bidder for Perrigo, however, and used a $230 per share takeover while analyzing possible deals. PRICE ACTION: In afternoon trading, Mylan shares rose 5.6% to $70.58, Teva added 3.7% to $65.53 and Perrigo fell 2.5% to $193.99.
14:23 EDTPRGOMylan jumps after Dow Jones says Teva considering bid
Subscribe for More Information
April 16, 2015
14:12 EDTPRGOPerrigo announces launch of generic version of Kenalog nasal spray
Subscribe for More Information
10:15 EDTPRGOOptions with decreasing implied volatility
Subscribe for More Information
06:05 EDTWMTFormer Wal-Mart CEO Duke heads to Carlyle Group, WSJ reports
Subscribe for More Information
April 15, 2015
09:02 EDTPRGORBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
06:09 EDTPRGOStocks with implied volatility below IV index mean; FXE PRGO
Subscribe for More Information
April 14, 2015
18:32 EDTWMTCourt rules Wal-Mart can reject shareholder proposal on gun sales, WSJ says
Subscribe for More Information
10:50 EDTPRGOOptions with increasing implied volatility
Subscribe for More Information
April 13, 2015
10:48 EDTPRGOOptions with increasing implied volatility
Options with increasing implied volatility: CLDN WETF EWH FOSL FXI TLM PRGO ATHN SYMC MAC
10:34 EDTHMHCAnalyst predicts consolidation in educational products space
The shares of Scholastic (SCHL) are climbing after Citigroup wrote that the company will probably be acquired by Houghton Mifflin Harcourt (HMHC). Scholastic develops educational products for children, including books and technology products. Houghton Mifflin Harcourt publishes textbooks used in K-12 schools around the world. WHAT'S NEW: Houghton Mifflin is "very likely" to buy Scholastic, Citi analyst Jason Bazinet wrote in a note to investors earlier today. The assets of Scholastic "fit naturally" with those of Houghton Mifflin, since both companies publish materials for K-12 students, the analyst stated. Houghton Mifflin's reluctance to return capital to shareholders, along with a lack of suitable targets in the K-12 space, further convince Bazinet that the deal will probably take place, the analyst stated. The acquisition would increase the value of Houghton Mifflin's stock to $30, wrote Bazinet, who increased his price target on the shares to $29 from $23. He kept a Buy rating on the stock. PRICE ACTION: In early trading, Scholastic rose 1.3% to $40, while Houghton Mifflin advanced 1.5% to $24.
07:56 EDTPRGOMylan, Teva, Perrigo price targets raised at JPMorgan
Subscribe for More Information
06:49 EDTPRGOMylan notifies Perrigo of HSR filing regarding proposed acquisition
Mylan N.V. (MYL) announced that it has provided Perrigo (PRGO) with notice of its filing of the premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.
06:25 EDTHMHCHoughton Mifflin 'very likely' to acquire Scholastic, says Citigroup
Subscribe for More Information
April 12, 2015
15:43 EDTWMTWal-Mart's Walton family puts shares in newly formed trust, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use